Emergent begins Phase Ib/II TRU-016 study
The company expects to recruit around 114 bendamustine-naive patients with a confirmed diagnosis of relapsed CLL and who have failed up to three previous treatments. In the Phase
South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.